A Phase I/IIa, Randomized Double Blind, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus

Trial Profile

A Phase I/IIa, Randomized Double Blind, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Nu 3 (Primary)
  • Indications Diabetic foot ulcer
  • Focus Adverse reactions
  • Sponsors Lakewood Amedex
  • Most Recent Events

    • 04 Dec 2017 According to a Lakewood-Amdex media release, positive top-line data from this trial will be presented at the LD MICRO Main Event.
    • 29 Sep 2017 According to a Lakewood Amedex media release, the company will present top-line data at the BioPharm America Conference 2017.
    • 27 Sep 2017 According to a Lakewood Amedex media release, Dr. Alexander Reyzelman is Principal Investigator of the study
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top